secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bioventus Inc. (BVS)
CIK:        0001665988
Form:       8-K
Filed at:   2021-10-29T23:59:59+00:00
Accession:  0001193125-21-313521
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.01, 2.03, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioventus completes Misonix acquisition; $183M cash plus 18.3M shares issued
----------------------------------------------------------------------------

- Misonix shareholders received $28 cash or 1.6839 BVS shares per share; total consideration $182.99M cash and 18.34M BVS shares.
- New $262M term loan added to finance the merger; $80M of existing Bioventus term loan prepaid.
- Stavros Vizirgiankis and Patrick Beyer appointed to Bioventus board effective closing.
- Combined company targets $15B addressable market; expects double-digit revenue growth.
- Misonix becomes wholly owned subsidiary of Bioventus; operations continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1665988/000119312521313521/0001193125-21-313521-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1665988/000119312521313521/d248592d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-313521

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer